References
- 1. Singh R. Review literature on uterine carcinosarcoma. J Can Res Ther 2014;10:461-8.
- 2. McCluggage WG. Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol. 2010 Mar;17(2):122-9.
- 3. F. Amant, E. Steenkiste, K. Schurmans, et al. Immunohistochemical expression of CD10 antigen in uterine adenosarcoma. Int J Gynecol Cancer, 14 (2004), pp. 1118-21.
- 4. D’Angelo E, Prat J. Pathology of mixed Mullerian tumours. Best Pract Res Clin Obstet Gynaecol. 2011 Dec;25(6):705-18.
- 5. Chaudhary YS, Illahi F, Moatasim A. Carcinosarcoma uterine unusual histologic presentation. Rawal Med J 2009;34:120-2.
- 6. Wolfson AH, Wolfson DH, Sittler SY, Breton L, Markoe AM, Schwade JG, et al. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 1994;52:56-62
- 7. Yildirim Y, Inal MM, Sanci M, Yildrim YK, Mit T, Polat M, et al. Development of uterine sarcoma after tamoxifen treatment for breast cancer: A report four cases. Int J Gynecol Cancer 2005;15:1239-42.
- 8. Arenas M, Rovirosa A, Hernandez V, Ordi J, Jarcano S, Mellado B, et al. Uterine sarcomas in breast cases patients treated with tamoxifen. Int J Gynecol Cancer 2006;16:861-5.
- 9. Wysowki DK, Honig SF, Beitz J. Uterine sarcoma associated with tamoxifen use. N Engl J Med 2002;346:1832-3.
- 10. Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. Tamoxifen related uterine carcinosarcomas occur under/after prolonged treatment: Report of five cases and review of literature. Int J Gynecol Cancer 2002;12:496-500.
- 11. Hubalek M, Ramoni A, Muller-holzner E, Marth C. Malignant mixed mesodermal tumour after tamoxifen therapy for breast cancer. Gynecol Oncol 2004;95:264-6.
- 12. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 2007;31:1653-61.
- 13. Ablen EC, Smit VT, Wessels JW, de Deleeuw WJ, Cornelisse CJ, Fleuren GJ. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed Mullerian tumours. J Pathol 1997;183:424-31.
- 14. Kuyumcuoglu U, Kale A. Homologous type malignant mixed Mullerian tumour of the uterus presenting as cervical mass. J Chin Med Assoc 2009;72:533-5
- 15. Molpus KL, Redline-Frazier S, Reed G, Burnett LS, Jones HW 3 rd . Postoperative pelvic irradiation in early stage uterine mixed Mullerian tumours. Eur J Gynecol Oncol 1998;19:541-6.
- 16. Menczer J, Levy T, Piura B, Chetrit A, Altaraj M, Meirovitz M, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol 2005;97:166-70.
- 17. Wong L, See HT, Khoo-Tan HS, Low JS, Ng WT, Low JJ. Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed Mullerian tumours of the uterine sarcomas. Int J Gynecol Cancer 2006;16:1364-9.
- 18. Felix AS1, Stone RA, Bowser R, Chivukula M, Edwards RP, Weissfeld JL, Linkov F. Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers. Int J Gynecol Cancer. 2011 Jul;21(5):877-84.
- 19. Tong SY1, Lee JM, Choi YJ, Lee JK, Kim JW, Cho CH, Kim SM, Park SY, Park CY, Kim KT. The comparison of clinicopathological characteristics in primary malignant mixed műllerian tumour with epithelial endometrial carcinoma. Aust N Z J Obstet Gynaecol. 2012 Feb;52(1):44-8.
- 20. Reed NS: Uterine sarcomas--the biggest challenge? Clin Oncol (R Coll Radiol) 2002, 14(1):50-3.
- 21. Norris HJ, Taylor HB: Postirradiation sarcomas of the uterus. Obstet Gynecol 1965, 26(5):689-94.
- 22. Press MF, Scully RE: Endometrial “sarcomas” complicating ovarian thecoma, polycystic ovarian disease and estrogen therapy. Gynecol Oncol 1985, 21(2):135-54.
- 23. Clement PB, Oliva E, Young RH: Mullerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifenassociated endometrial lesions. Int J Gynecol Pathol 1996, 15(3):222-9.
- 24. Clement PB, Scully RE: Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol 1990, 21(4):363-81.
- 25. Verschraegen CF, Vasuratna A, Edwards C, Freedman R, Kudelka AP, Tornos C, Kavanagh JJ: Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience. Oncol Rep 1998, 5(4):939-44.
- 26. Gallardo A, Prat J: Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol 2009, 33(2):278-88.
- 27. Zaloudek CJ, Norris HJ: Adenofibroma and adenosarcoma of the uterus: a clinicopathologic study of 35 cases. Cancer 1981, 1548(2):354-66.
- 28. Krivak TC, Seidman JD, McBroom JW, MacKoul PJ, Aye LM, Rose GS: Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival. Gynecol Oncol 2001, 83(1):89-94.
- 29. Clement PB, Scully RE: Mullerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of mullerian mixed tumor. Cancer 1974, 34(4):1138-49.